Device deal making is back in a big way, despite the munificence of venture funds.
A sudden increase in seed and series A funding bodes well for the year ahead.
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
The quest for the Grail is beset with challenges.
In terms of private investments, 2020 was the year of the liquid biopsy.